CD47 and central nervous system cancer: Although both M1 and M2 subtypes demonstrate a robust response to CD47-SIRPα disruption, the stronger M1 antitumor response and associated cytokine profile suggest a clinical value from enhancing the M1 macrophage response toward gliomas and other solid tumors [50].